key: cord-0888636-vdxdyg8u
authors: O’Horo, John C.; Williams, Amy W.; Badley, Andrew D.
title: A Blueprint to Control the SARS-CoV-2 Pandemic
date: 2021-03-26
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.03.013
sha: d8219102c703bf3a2f748bab474e1e7cd29a9181
doc_id: 888636
cord_uid: vdxdyg8u

nan

understanding SARS-CoV-2 biology, developing accurate diagnostics, testing therapies, and validating vaccination approaches. Unfortunately, translating these into effective public health interventions has been at best uneven. Although the pandemic still rages, many are discussing how and when to reopen businesses, society, and economies. These decisions must be informed in a science-based understanding of how control of the pandemic can be achieved.

A basic principal of understanding infectious diseases spread is the concept of ID 50 (Infectious Dose 50), or the number of pathogens (in this case, number of SARS-CoV-2 viruses) that causes infection in 50% of those who are exposed. The ID 50 for a given pathogen depends on (i) the basic reproduction number (R 0 , or the expected number of cases directly generated by one case) and (ii) host susceptibility. Those variables are not static; for example, the B.1.1.7 (United Kingdom) variant of SARS CoV-2 is believed to have a higher R 0 that original SARS-CoV-2 strains. The number of human conditions that appear to impact host susceptibility to infection (for example Diabetes, Obesity, and intrinsic errors in Type 1 interferon signaling pathways) continues to grow as the outbreak continues. While those variables may explain, in part, heterogeneity in disease outcomes on an individual basis, within large populations they are generally stable and understanding their influence can inform policy for re-opening of societies. Implicit in the concept of ID 50 , is the understanding that if the number of pathogens if greater than ID 50 , then more hosts will become infected, and if the number of pathogens is less than ID 50 , then fewer hosts will become infected. In other words, infectious rates follow a dose response relationship.

In the case of SARS-CoV-2, at least five lines of evidence suggest that infection follows of SARS-CoV-2 infection following exposure to an infected individual is inversely proportional to proximity of exposure and recovery of droplets in the environment decreases with increasing distance according to Stoke's law 2 (iii) Efficacy of respiratory transmission of SARS-CoV-2 estimated by modelling, indicates that risk decreases both with increasing room size, and increased frequency of air changes per hour 3 -consistent with a dose response effect. (iv) clinical success of antiviral agents for SARS-CoV-2 demonstrates that treatment success is associated with reduced viral load. 4 (v) Higher viral loads as measured by cycle threshold values are associated with increase infectiousness in cell culture models. 5 The practical significance of SARS-CoV-2 following a dose response relationship is seen at two levels: first in terms of symptoms, and second in terms of transmissibility ( Figure 1A) .

Emerging data suggest that higher SARS-CoV-2 viral loads are associated with worsened disease severity, 6 which aligns with prior observations that disease is more severe with higher viral loads in Cytomegalovirus, Herpes Simplex virus, Hepatitis B virus and Hepatitis C virus infections. Congruently, asymptomatic carriers of SARS-CoV-2 appear to be less efficient at transmitting SARS-CoV-2 7 possibly due to reduced viral loads, but also likely as a result of fewer symptoms, by definition, in asymptomatic individuals. Because the symptoms of COVID-19 (coughing, in particular) increasing effective droplet spread, fewer symptomatic cases translate to fewer droplets produced at or above the ID 50 over shorter distances.

It is good news that SARS-CoV-2 follows a dose response because any intervention that reduces virus copy number in infected hosts or reduces the proportion of exposed individuals which shed virus, will also reduce viral spread within populations. Knowing this, how can societies maximally control the spread of the pandemic? We posit that the following three interventions will be required in concert to achieve maximal control of the SARS-CoV-2 pandemic.

J o u r n a l P r e -p r o o f of symptomatic infections by as much as 95%. Less is known about the impact of such vaccines of SARS-CoV-2 viral loads and consequent shedding. Rhesus macaques vaccinated with Ad26, then challenged with high dose SARS-CoV-2 were followed for disease and viral load; vaccinated monkeys had fewer symptoms, less pathology and greatly reduced viral loads (> 3.0 log reductions) in both BAL samples and Nasopharyngeal swabs. 8 Humans vaccinated with the ChAdOx1 nCoV-19 (AZD1222) vaccine, and prospectively monitored for proportion which shed virus by NP swab, showed that even a single dose of vaccine reduced viral shedding by 67%. 9 Thus, vaccination is very likely to reduce transmission, and early evidence supports that contention in a large population based study in Israel. 10 One of the enigma's of understanding immune mediated protection is the concept of Immune correlates of protection, or which element of the immune response is associated with protection from disease. An extreme example is seen with prophylactic HIV vaccines: most vaccines tested generate robust immune responses of virtually any immune element assesses, but few if any confer protection against disease. In the case of SARS-CoV2 monoclonal antispike antibodies alone are sufficient to prevent human infection, 11 demonstrating de facto that one immune correlate of protection is antibody. That in turn informs our understanding of the protection conferred after recovery from natural infection. Recent data demonstrate that while antibody levels decay over time in recovered patients with a half-life of ~83 days, memory B cells, including those producing receptor binding domain antibodies, increase over the first 4-5 months post infection, strongly suggesting that natural infection produces lasting immunity to reinfection. 12 Indeed, although re-infections with SARS-CoV-2 have been reported, the rate of infection in subjects who are seropositive as a result of natural infection is significantly less than in seronegatives. 13 Accordingly, recovery from natural infection, impacts disease susceptibility and will contribute to control of the pandemic. Analyses have shown efforts which reduce crowds by cancelling public events and limiting private gatherings reduced infection rates, as did restrictions on schools and workplaces. 14 However, for these to be effective, the population has to adhere to the measures meticulously.

Compliance with NPI's has reduced over time, and the impact of enacting and discontinuing them can lag for weeks, leading to the 'seesaw' pattern of infections seen last year. As the impact of NPI's becomes increasingly apparent, it is critical to maintain this jointly with other interventions described Treatment as prevention. The concept of treatment as control reached maturity in the HIV epidemic, and we now know definitively that identifying and treating individuals for HIV reduces the ability of an infected individual to spread infection. 15 So too is likely the case for SARS-CoV-2. Returning the concept of infectiousness operating on a dose response curve, and given that treatments with remdesivir and spike monoclonal antibodies, reduce SARS-CoV-2 viral load, early and effective treatments are likely to reduce the ability of an infected individuals to spread virus by two means. First by implementing quarantine and other isolation interventions, and second by reducing the viral load in a treated individual, therapy reducing her/his ability to spread virus ( Figure 1B) .

The remarkable development of accurate diagnostics, effective therapies and preventative vaccines for SARS-CoV-2 have positioned societies to think about re-opening, however to be safe and effective, we propose an approach that maximizes the synergy of the three individually successful interventions of early diagnosis and treatment, Public health J o u r n a l P r e -p r o o f

Receptor-independent infection of murine coronavirus: analysis by spinoculation

Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and metaanalysis

Dose-response Relation Deduced for Coronaviruses from COVID-19, SARS and MERS Meta-analysis Results and its Application for Infection Risk Assessment of Aerosol Transmission

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

Viral dynamics in mild and severe cases of COVID-19

The assessment of transmission efficiency and latent infection period in asymptomatic carriers of SARS-CoV-2 infection

SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks. medRxiv

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Patterns of covid-19 pandemic dynamics following deployment of a broad national immunization program

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Estimating worldwide effects of non-pharmaceutical interventions on COVID-19 incidence and population mobility patterns using a multiple-event study

Successful treatment of HIV eliminates sexual transmission. The Lancet